Results 161 to 170 of about 615,914 (313)

Chemically contaminated aquatic food resources and human cancer risk: retrospective [PDF]

, 1991
Dawe, C. J., Farrington, J. W., Fouts, J. R., Harshbarger, J. C., Murchelano, R. A., Ozonoff, D., Pritchard, J. B., Stegeman, J. J.   +7 more
core   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Network Analysis of Predicted Therapeutic Symptoms in National Health Insurance Herbal Prescriptions. [PDF]

Life (Basel)
Jang S, Lee A, Kho C.
europepmc   +1 more source

Experimental Organism Benign Teratoma Neoplasm [PDF]

, 2020
openaire   +1 more source

Checkpoint blockade and the stem‐like T cell trade‐off

Molecular Oncology, EarlyView.
Stem‐like T cells are key to the success of programmed cell death protein 1 (PD1) blockade, as they sustain long‐term anti‐tumor response by continuously generating effector CD8+ T cells. However, how these cells are maintained in cancer is not fully understood. Hor et al.
Julie M. Mazet, Johanna A. Joyce
wiley   +1 more source

Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy. [PDF]

Clin Transl Med
Martino EA, Caserta S, Skafi M, Alvaro ME, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Mendicino F, Vigna E, Morabito F, Gentile M.   +12 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Carcinogenicity of atrazine, alachlor, and vinclozolin. [PDF]

Lancet Oncol
Cattley RC, De Roos AJ, Mandrioli D, Pearce N, Pronk A, Soshilov A, Abarikwu SO, Baldi I, Barr DB, Freeman LEB, Bortoli S, Connolly A, Dalvie MA, Ferreira MJ, Genter MB, Le Hégarat L, Lorenzetti S, McLaughlin JR, Møller P, Montagner CC, Silveira HCS, Toyoda T, Volle DH, Benbrahim-Tallaa L, de Conti A, Facchin C, Kunzmann AT, Madia F, Pasqual E, Aix ML, Deng X, Dongoran RA, Olanipekun MT, Suonio E, Viegas S, Mattock H, Wedekind R, Schubauer-Berigan MK.   +37 more
europepmc   +1 more source

Experimental Organism Benign Nephroblastoma Neoplasm [PDF]

, 2020
openaire   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source